# Mike Rosenbluth

> Mike Rosenbluth is the Founder and CEO of Swing Therapeutics, the San Francisco-based company behind Stanza - the first FDA-authorized prescription digital therapeutic for fibromyalgia symptoms. A Stanford-trained mechanical engineer with a UC Berkeley PhD in Bioengineering, Rosenbluth spent years at McKinsey, a VC firm (Versant Ventures), and cancer diagnostics company Veracyte before founding Swing in 2019. His company's landmark PROSPER-FM Phase 3 trial results were published in The Lancet in 2024, and Swing has raised over $30 million to bring evidence-based, non-drug behavioral therapy to the estimated 4 million Americans with fibromyalgia.

- **Role:** Founder & CEO at Swing Therapeutics, Inc.
- **Organizations:** Swing Therapeutics, Inc., Veracyte, Inc., Versant Ventures, McKinsey & Company, UC Berkeley, Stanford University
- **Nationality:** American
- **Education:** BS/MS Mechanical Engineering, Stanford University, PhD Bioengineering, University of California, Berkeley
- **Known for:** Founded Swing Therapeutics in 2019 and led it to become the first company with an FDA-authorized prescription digital therapeutic for fibromyalgia (Stanza), Oversaw the PROSPER-FM Phase 3 clinical trial - the largest medical device study ever conducted for fibromyalgia - published in The Lancet in July 2024, Raised over $30 million in venture funding for Swing Therapeutics, including a Series B in 2025

## Career timeline

- **1996-2002** — BS and MS in Mechanical Engineering at Stanford University
- **2002-2008** — PhD in Bioengineering at UC Berkeley under Dr. Dan Fletcher
- **2008-2012** — Engagement Manager at McKinsey & Company
- **2012-2014** — Investment Professional at Versant Ventures
- **2014-2016** — Vice President of Pulmonology at Veracyte, Inc.
- **2016-2019** — Vice President, Strategy and Business Development at Veracyte, Inc.
- **2019** — Founded Swing Therapeutics, Inc.
- **2022** — Closed $10.3M Series A led by JAZZ Venture Partners; launched PROSPER-FM pivotal Phase 3 trial
- **2023-05** — Stanza receives FDA De Novo marketing authorization - first digital therapeutic for fibromyalgia symptoms
- **2024-07** — PROSPER-FM Phase 3 results published in The Lancet; largest medical device study ever for fibromyalgia
- **2025-09** — Swing Therapeutics raises $11M Series B; Corey McCann (former Pear Therapeutics CEO) joins board

## Achievements

- Founded Swing Therapeutics in 2019 and led it to become the first company with an FDA-authorized prescription digital therapeutic for fibromyalgia (Stanza)
- Oversaw the PROSPER-FM Phase 3 clinical trial - the largest medical device study ever conducted for fibromyalgia - published in The Lancet in July 2024
- Raised over $30 million in venture funding for Swing Therapeutics, including a Series B in 2025
- Secured FDA Breakthrough Device Designation for Stanza prior to De Novo authorization
- Achieved 73% patient improvement rate (vs. 22.2% control) in Phase 3 trial with no adverse events
- Secured insurance coverage for Stanza through Highmark
- Built Swing Care, a virtual specialty clinic now operating in Illinois, Tennessee, and Texas

## Latest updates

- **2025-09** — Swing Therapeutics raised $11M Series B; former Pear Therapeutics CEO Corey McCann joined the board
- **2025-02** — Highmark announced coverage for Stanza, expanding insurance access for fibromyalgia patients
- **2024-07** — Phase 3 PROSPER-FM trial results published in The Lancet, the largest fibromyalgia medical device study ever

## Links

- Website: https://swingtherapeutics.com
- LinkedIn: http://www.linkedin.com/in/mikerosenbluth
- Twitter/X: https://twitter.com/swingtx

---

Profile page: https://yespress.io/mike-rosenbluth
Published by YesPress — https://yespress.io
Last updated: 2026-05-13